Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

Compounded Nonsterile Preparations and FDA-Approved Commercially Available Liquid Products for Children: A North American Update

Richard Parrish
* ORCID logo ,
Lisa D. Ashworth
,
Raimar Löbenberg
ORCID logo ,
Sandra Benavides
,
Jeffrey J. Cies
,
Robert B. MacArthur
Version 1 : Received: 3 March 2022 / Approved: 8 March 2022 / Online: 8 March 2022 (08:24:35 CET)
Version 2 : Received: 9 March 2022 / Approved: 10 March 2022 / Online: 10 March 2022 (08:26:21 CET)
Version 3 : Received: 4 April 2022 / Approved: 5 April 2022 / Online: 5 April 2022 (10:17:10 CEST)

A peer-reviewed article of this Preprint also exists.

Parrish II, R.H.; Ashworth, L.D.; Löbenberg, R.; Benavides, S.; Cies, J.J.; MacArthur, R.B. Compounded Nonsterile Preparations and FDA-Approved Commercially Available Liquid Products for Children: A North American Update. Pharmaceutics 2022, 14, 1032. https://doi.org/10.3390/pharmaceutics14051032 Parrish II, R.H.; Ashworth, L.D.; Löbenberg, R.; Benavides, S.; Cies, J.J.; MacArthur, R.B. Compounded Nonsterile Preparations and FDA-Approved Commercially Available Liquid Products for Children: A North American Update. Pharmaceutics 2022, 14, 1032. https://doi.org/10.3390/pharmaceutics14051032

Abstract

The purpose of this work was to evaluate the suitability of recently US Food and Drug Administration (US-FDA) approved and marketed oral liquid, powder, or granule products for children in North America, to identify the next group of Active Pharmaceutical Ingredients (APIs) that have high potential for development as commercially available FDA-approved finished liquid dosage forms , and to propose lists of compounded nonsterile preparations (CNSPs) that should developed as commercially available FDA-approved finished liquid dosage forms as well as those that pharmacists should continue to compound extemporaneously. Through this identification and categorization process, the pharmaceutical industry, government, and the professions are encouraged to continue to work together to improve the likelihood that patients will receive high quality standardized extemporaneous CNSPs and US-FDA-approved products.

Keywords

active pharmaceutical ingredient; compounded drug; compounding; extemporaneous formulation; manufactured material; medication; monograph; pediatric; reference standards

Subject

Medicine and Pharmacology, Pharmacology and Toxicology

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Download PDF Download Supplementary

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0
Get PDF Supplementary Files Cite Share 0
Bookmark BibSonomy Mendeley Reddit Delicious
×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.